Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eugenol aspirin ester pharmaceutical compound, preparation and preparing method

A technology of eugenol aspirin ester and aspirin, applied in the field of eugenol aspirin ester medicinal compound and its formulation and preparation

Active Publication Date: 2008-09-24
LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And take eugenol as raw material to prepare other esters with dual effects, there is no report yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eugenol aspirin ester pharmaceutical compound, preparation and preparing method
  • Eugenol aspirin ester pharmaceutical compound, preparation and preparing method
  • Eugenol aspirin ester pharmaceutical compound, preparation and preparing method

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0050] The concrete preparation route of eugenol aspirin ester is as follows:

[0051]

[0052] In a 250ml three-neck flask equipped with an electromagnetic stirrer and a thermometer, add 3.6g of aspirin, 1ml of DMF, and 2.8g of thionyl chloride, stir and react at 60-75°C for 2-3 hours, and evaporate under reduced pressure For unreacted thionyl chloride, the resulting acid chloride was dissolved in 8ml of benzene or 8ml of chloroform for use. Add 3.3g eugenol and 5ml water into the reaction flask, add 16ml 5% NaOH solution and PEG-1000 at 5-10°C, stir, add the above-mentioned acid chloride solution to be used after 0.5 hours, and continue the reaction for 2-5 Hour. After static separation, the organic phase was concentrated under reduced pressure to obtain a solid, which was recrystallized from methanol to obtain a white crystalline product with a yield of 65% and a melting point of 71-72°C.

[0053] The present invention uses the eugenol aspirin ester medicinal compound ...

Embodiment 1

[0055] Prescription: Eugenol aspirin ester 25mg

[0056] Medium Chain Triglycerides 34-50mg

[0057] Soy Lecithin 20-30mg

[0058] Macrogol-12-hydroxystearate 20-30mg

[0059] Absolute ethanol 30-40mg

[0060] PEG-400 10-20mg

[0061] Water 180-300ml

[0062] Preparation method: dissolve eugenol aspirin ester in medium-chain triglycerides containing absolute ethanol, PEG-400, soybean lecithin, polyethylene glycol-12-hydroxystearate, and stir overnight at 37°C until equilibrium; By titrating the oil phase with water, a uniform and stable microemulsion of eugenol aspirin ester can be formed.

Embodiment 2

[0064] Prescription: Eugenol aspirin ester 25mg

[0065] Phospholipids 40-60mg

[0066] Cholesterol 10-40mg

[0067] Chloroform 20-30mg

[0068] water 2-3ml

[0069] Preparation method: Dissolve eugenol aspirin ester in a chloroform solution containing phospholipids and cholesterol, and evaporate the chloroform to form a phospholipid film; dissolve the phospholipid film with water, and form uniform liposomes through cell crushing and ultrasonication.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a compound for eugenol aspirin ester medicine, which has a structure as shown in formula (I). The compound has the characteristics of more obvious pharmacological effects and more stable structure. Aspirin is used as raw material, chloridized by acyle and has the esterification reaction in a menstruum; the compound can be prepared after re-crystallization. The compound for eugenol aspirin ester medicine is an effective medical component and can be used for treating various clinical high fever diseases by doctors for human beings and animals, in particular the high fever diseases caused by viral infection. And the compound can be used for solid preparation, liquid preparation, injection, ophthalmic preparation, ointment, suppository, pellicle, aerosol, or external preparation, so as to prevent thrombosis and fungal infection of the skin.

Description

technical field [0001] The invention relates to the technical field of medicine, specifically, it is a medicinal compound of eugenol aspirin ester with antipyretic, anti-inflammatory, analgesic, antithrombotic, antifungal and antiviral effects, and its preparation and preparation method , and pharmaceutical preparations in the form of solid preparations, liquid preparations, injections, ophthalmic preparations, ointments, suppositories, film preparations, aerosols or external preparations made of the compound as an active pharmaceutical ingredient. Background technique [0002] Eugenol is the main component of the volatile oil extracted from the dried buds of Eugenia caryophyllata Thumb, a traditional Chinese medicine. Pharmacological research results show that eugenol has antiviral, antibacterial, antipyretic, analgesic, anti-inflammatory, anti-oxidation, anti-ulcer, inhibition of intestinal motility, anti-diarrhea, anti-hypoxia, inhibition of arachidonic acid metabolism, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C69/86C07C67/08A61K31/621A61P29/00A61P31/00A61P7/02
Inventor 李剑勇张继瑜周绪正牛建荣魏小娟
Owner LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com